See more : Haymaker Acquisition Corp. III (HYACW) Income Statement Analysis – Financial Results
Complete financial analysis of Photocure ASA (PHCUF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Photocure ASA, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Exacompta Clairefontaine S.A. (EXAC.PA) Income Statement Analysis – Financial Results
- Naseej for Technology Co. (9538.SR) Income Statement Analysis – Financial Results
- LandBridge Company LLC (LB) Income Statement Analysis – Financial Results
- Miravant Medical Technologies Inc. (MRVT) Income Statement Analysis – Financial Results
- Nitto Denko Corporation (NDEKY) Income Statement Analysis – Financial Results
Photocure ASA (PHCUF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.photocure.com
About Photocure ASA
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 500.66M | 393.13M | 360.54M | 256.48M | 281.56M | 181.51M | 150.91M | 143.63M | 134.72M | 128.95M | 83.62M | 133.82M | 115.57M | 177.36M | 48.43M | 102.22M | 99.01M | 210.32M | 53.64M | 77.81M | 55.15M | 25.22M |
| Cost of Revenue | 26.14M | 22.70M | 24.05M | 18.51M | 22.51M | 17.15M | 12.01M | 9.34M | 8.22M | 7.00M | 6.83M | 9.41M | 11.07M | 9.12M | 5.54M | 19.07M | 17.33M | 22.25M | 13.43M | 13.07M | 9.51M | 5.83M |
| Gross Profit | 474.52M | 370.44M | 336.49M | 237.97M | 259.04M | 164.36M | 138.90M | 134.29M | 126.50M | 121.96M | 76.79M | 124.42M | 104.50M | 168.23M | 42.89M | 83.15M | 81.68M | 188.07M | 40.21M | 64.74M | 45.64M | 19.39M |
| Gross Profit Ratio | 94.78% | 94.23% | 93.33% | 92.78% | 92.00% | 90.55% | 92.04% | 93.50% | 93.90% | 94.57% | 91.83% | 92.97% | 90.42% | 94.86% | 88.56% | 81.34% | 82.50% | 89.42% | 74.96% | 83.21% | 82.75% | 76.88% |
| Research & Development | 2.07M | 3.34M | 4.32M | 13.84M | 13.64M | 19.15M | 32.59M | 22.96M | 31.34M | 32.55M | 33.98M | 50.08M | 66.19M | 90.17M | 78.98M | 84.30M | 112.10M | 38.20M | 38.24M | 31.72M | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.18M | 8.68M | 9.45M | 8.61M | 0.00 | -8.95M | -7.14M | -10.09M | 0.00 | 0.00 |
| Selling & Marketing | 334.94M | 303.43M | 259.87M | 187.81M | 148.74M | 121.30M | 96.43M | 79.93M | 73.40M | 54.56M | 68.42M | 70.19M | 50.18M | 35.40M | 24.98M | 45.92M | 0.00 | 9.44M | 7.51M | 10.41M | 0.00 | 0.00 |
| SG&A | 334.94M | 303.43M | 259.87M | 187.81M | 148.74M | 121.30M | 96.43M | 79.93M | 73.40M | 54.56M | 68.42M | 70.19M | 61.36M | 44.08M | 34.44M | 54.52M | 0.00 | 491.00K | 368.00K | 322.00K | 0.00 | 0.00 |
| Other Expenses | 109.70M | 112.66M | 78.13M | 59.53M | 53.93M | 47.62M | 55.08M | 47.26M | 43.75M | 40.47M | 46.24M | 43.40M | 34.32M | 26.47M | 20.08M | 11.69M | 57.03M | 76.73M | 64.09M | 78.16M | 99.30M | 128.92M |
| Operating Expenses | 446.71M | 419.44M | 342.32M | 261.18M | 216.31M | 188.07M | 184.10M | 150.15M | 148.48M | 127.59M | 148.63M | 163.67M | 161.87M | 160.71M | 133.49M | 150.52M | 169.13M | 115.42M | 102.70M | 110.20M | 99.30M | 128.92M |
| Cost & Expenses | 472.85M | 442.13M | 366.37M | 279.69M | 238.82M | 205.21M | 196.11M | 159.49M | 156.70M | 134.58M | 155.46M | 173.07M | 172.94M | 169.84M | 139.03M | 169.59M | 186.46M | 137.67M | 116.13M | 123.27M | 108.81M | 134.75M |
| Interest Income | 11.71M | 2.34M | 1.81M | 5.66M | 1.70M | 1.19M | 2.36M | 2.39M | 995.00K | 4.14M | 5.55M | 10.40M | 12.27M | 15.15M | 11.10M | 13.11M | 14.22M | 6.97M | 4.10M | 3.15M | 3.13M | 6.75M |
| Interest Expense | 26.33M | 25.80M | 23.83M | 7.03M | 735.00K | 272.00K | 219.00K | 86.00K | 107.00K | 3.00K | 10.00K | 5.00K | 2.36M | 4.58M | 13.55M | 16.10M | 14.22M | 36.00K | 66.00K | 103.00K | -7.76M | -6.77M |
| Depreciation & Amortization | 27.69M | 24.38M | 24.13M | 9.66M | 5.73M | 13.21M | 12.11M | 7.85M | 3.90M | 1.47M | 1.46M | 1.61M | 1.13M | 1.32M | 1.45M | 1.55M | 1.39M | 1.34M | 1.13M | 1.53M | 1.68M | 1.27M |
| EBITDA | 63.75M | -20.75M | 16.82M | -15.77M | 44.31M | -10.49M | -33.10M | -8.01M | -18.09M | -4.16M | -66.98M | -31.67M | -43.96M | 23.99M | -75.05M | -67.12M | -73.57M | 79.68M | -37.28M | -43.69M | -51.98M | -108.26M |
| EBITDA Ratio | 12.73% | -5.14% | 9.30% | 2.32% | 20.94% | 2.04% | -21.93% | -24.57% | -6.53% | 2.33% | -73.78% | -21.97% | -38.04% | 13.52% | -126.99% | -45.71% | -86.93% | 38.23% | -97.91% | -62.06% | -94.24% | -429.20% |
| Operating Income | 27.81M | -49.00M | 9.39M | -13.34M | 42.74M | -37.90M | -45.20M | -15.86M | -21.99M | -5.63M | -71.85M | -39.25M | -57.37M | 7.52M | -78.95M | -67.37M | -87.45M | 78.34M | -47.25M | -40.86M | -53.66M | -109.53M |
| Operating Income Ratio | 5.55% | -12.46% | 2.60% | -5.20% | 15.18% | -20.88% | -29.95% | -11.04% | -16.32% | -4.37% | -85.92% | -29.33% | -49.64% | 4.24% | -163.03% | -65.91% | -88.33% | 37.25% | -88.09% | -52.51% | -97.28% | -434.23% |
| Total Other Income/Expenses | -18.07M | -22.13M | -25.83M | 2.83M | 3.17M | 1.19M | 3.62M | 28.64M | -6.08M | -1.02M | 4.99M | 8.24M | -16.86M | 10.57M | 2.45M | 2.99M | 12.48M | 6.39M | 8.78M | 136.00K | 10.89M | 13.52M |
| Income Before Tax | 9.74M | -71.13M | -31.66M | -33.23M | 45.90M | -36.71M | -41.58M | 12.78M | -28.07M | -6.65M | -66.85M | -31.01M | -47.46M | 18.09M | -76.50M | -64.38M | -74.97M | 84.73M | -38.47M | -45.32M | -42.77M | -96.01M |
| Income Before Tax Ratio | 1.95% | -18.09% | -8.78% | -12.95% | 16.30% | -20.23% | -27.55% | 8.90% | -20.84% | -5.16% | -79.95% | -23.17% | -41.07% | 10.20% | -157.97% | -62.98% | -75.72% | 40.29% | -71.72% | -58.25% | -77.54% | -380.62% |
| Income Tax Expense | 8.76M | 723.00K | -759.00K | -10.82M | 14.07M | -6.00K | -6.88M | -22.53M | 8.11M | 18.05M | -8.20M | -890.00K | -39.95M | 15.15M | -361.23M | 19.10M | 0.00 | 6.07M | 8.58M | -4.65M | 0.00 | 0.00 |
| Net Income | 979.00K | -71.86M | -30.90M | -22.40M | 31.83M | -36.71M | -34.70M | 35.31M | -36.18M | -24.70M | -58.95M | -47.90M | -7.51M | 18.09M | 312.38M | -64.38M | -74.97M | 85.08M | -38.21M | -45.03M | -42.77M | -96.01M |
| Net Income Ratio | 0.20% | -18.28% | -8.57% | -8.73% | 11.31% | -20.22% | -22.99% | 24.58% | -26.85% | -19.15% | -70.50% | -35.79% | -6.50% | 10.20% | 645.04% | -62.98% | -75.72% | 40.45% | -71.23% | -57.87% | -77.54% | -380.62% |
| EPS | 0.04 | -2.66 | -1.15 | -0.91 | 1.46 | -1.70 | -1.61 | 1.64 | -1.69 | -1.16 | -2.78 | -2.25 | -0.35 | 0.84 | 14.16 | -2.91 | -3.40 | 3.98 | -2.17 | -2.56 | -2.44 | -5.51 |
| EPS Diluted | 0.04 | -2.66 | -1.15 | -0.91 | 1.46 | -1.70 | -1.61 | 1.64 | -1.68 | -1.16 | -2.77 | -2.24 | -0.35 | 0.83 | 14.14 | -2.91 | -3.39 | 3.97 | -2.17 | -2.56 | -2.44 | -5.51 |
| Weighted Avg Shares Out | 27.11M | 27.03M | 26.84M | 24.62M | 21.78M | 21.58M | 21.55M | 21.50M | 21.39M | 21.32M | 21.24M | 21.26M | 21.35M | 21.59M | 22.06M | 22.09M | 22.07M | 21.31M | 17.58M | 17.58M | 17.50M | 17.42M |
| Weighted Avg Shares Out (Dil) | 27.13M | 27.03M | 26.84M | 24.62M | 21.83M | 21.63M | 21.55M | 21.53M | 21.47M | 21.34M | 21.30M | 21.35M | 21.54M | 21.86M | 22.09M | 22.09M | 22.15M | 21.37M | 17.61M | 17.59M | 17.50M | 17.42M |
Photocure ASA: Results for the third quarter of 2024
OSLO, Norway , Nov. 13, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million), and EBITDA of NOK 5.0 million (NOK 3.3 million) for...
Source: https://incomestatements.info
Category: Stock Reports